A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder

OBJECTIVE: To test the safety of ublituximab, a B cell depleting agent, as add-on therapy in the acute treatment of relapses of neuromyelitis optica spectrum disorder. METHODS: We conducted an open-label phase 1b safety and proof-of-concept trial in 5 subjects with aquaporin-4 (AQP4)-immunoglobulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mealy, Maureen A., Levy, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636936/
https://www.ncbi.nlm.nih.gov/pubmed/31232925
http://dx.doi.org/10.1097/MD.0000000000015944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636936/
https://www.ncbi.nlm.nih.gov/pubmed/31232925
http://dx.doi.org/10.1097/MD.0000000000015944

Ejemplares similares